EPISODE · Oct 26, 2021 · 33 MIN
Novel targeted therapies for NSCLC: Exploring HER2 dysregulation
from touchPODCAST · host touchpodcast
touchPANEL DISCUSSION for touchONCOLOGY Listen to a panel of experts discuss the latest clinical research in HER2 dysregulation and potential HER2-targeted therapies in NSCLC. The experts Prof. Egbert Smit – Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands Dr Jarushka Naidoo – Beaumont Hospital, Dublin, Ireland Dr Katerina Politi – Yale School of Medicine, New Haven, CT, US This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent educational grant from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchoncologyime.org/her2-dysregulation-nsclc-targeted-therapy/
Embed this episode
Ready to play
Novel targeted therapies for NSCLC: Exploring HER2 dysregulation
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.